MRK

Merck & Co. Inc. Healthcare - Pharmaceuticals Investor Relations →

NO
17.3% ABOVE
↓ Approaching Was 18.1% last week
-15% -10% -5% 0% 5% 10% 15%+
Buy Threshold $97.30
14-Week RSI 70
Rel. Volume (14w) This week's trading vs. the 14-week average 1.3x
Buyers vs. Sellers (14w) Are up-weeks or down-weeks getting more volume? 1.28

Merck & Co. Inc. (MRK) closed at $114.18 as of 2026-03-20, trading 17.3% above its 200-week moving average of $97.30. The stock is currently moving closer to the line, down from 18.1% last week. The 14-week RSI sits at 70, indicating neutral momentum.

Trading volume is running at 1.3x of its 14-week average, which is in the normal range. The balance between buying and selling volume (1.28 ratio) is neutral — neither side is clearly dominating.

Over the past 3302 weeks of data, MRK has crossed below its 200-week moving average 24 times. On average, these episodes lasted 30 weeks. Historically, investors who bought MRK at the start of these episodes saw an average one-year return of +10.9%.

With a market cap of $282.3 billion, MRK is a large-cap stock. The company generates a free cash flow yield of 4.2%. Return on equity stands at 36.9%, indicating strong profitability. The stock trades at 5.4x book value.

Over the past 33.2 years, a hypothetical investment of $100 in MRK would have grown to $1796, compared to $2683 for the S&P 500. MRK has returned 9.1% annualized vs 10.4% for the index, underperforming the broader market over this period.

Free cash flow has been declining at a -5.6% compound annual rate. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.

Business Health

Annual financials — how the underlying business has performed over the past several years.

Cash Flow Free cash flow & net income ($M)

Revenue Annual revenue ($M) — business growth proxy

Total Debt Balance sheet debt ($M)

ROIC Return on invested capital (%)

FCF Yield Free cash flow / market cap (%) — Yartseva signal

Gross Margin Pricing power & competitive moat (%)

Shares Outstanding Buybacks vs dilution (millions)

Growth of $100: MRK vs S&P 500

Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.

What Happens After MRK Crosses Below the Line?

Across 14 historical episodes, buying MRK when it crossed below its 200-week moving average produced an average return of +10.0% after 12 months (median +7.0%), compared to +4.6% for the S&P 500 over the same periods. 64% of those episodes were profitable after one year. After 24 months, the average return was +31.8% vs +16.5% for the index.

Each line shows $100 invested at the moment MRK crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.

Advertisement

Historical Touches

MRK has crossed below its 200-week MA 24 times with an average 1-year return of +10.9% after recovery.

Crossed BelowRecoveredWeeksMax Depth1-Year ReturnReturn Since Touch
May 1970Jun 197021.8%+30.7%+54264.8%
Jul 1970Sep 1970812.4%+29.9%+55449.2%
Jul 1974Feb 19752830.5%+16.5%+32184.5%
Mar 1975Apr 197514.0%+7.4%+29571.1%
Apr 1975Apr 197510.3%+4.0%+28305.2%
Jul 1975Nov 19751511.4%-4.5%+27617.5%
Dec 1975Aug 19763911.7%-11.8%+27342.7%
Oct 1976Dec 197811127.3%-27.9%+27407.1%
Jun 1982Aug 198299.0%+29.9%+24750.7%
Jul 1984Jul 198410.2%+51.2%+19742.3%
Mar 1993Apr 199345.6%-8.5%+2019.2%
Jun 1993Nov 19947422.8%-10.3%+1974.8%
Jun 2001Jul 200158.7%-19.0%+370.3%
Aug 2001Jul 200625648.2%-20.6%+361.7%
Jun 2008Nov 20097638.1%-26.8%+501.6%
Apr 2010Jun 2010910.9%+1.0%+472.4%
Jun 2010Jul 201013.8%+8.7%+490.7%
Jul 2010Aug 201063.1%+8.1%+479.7%
Nov 2010Nov 201031.0%+8.4%+476.4%
Jan 2011Apr 2011126.4%+17.3%+478.3%
Aug 2011Sep 201183.9%+45.8%+510.4%
Nov 2017Nov 201721.9%+42.2%+182.0%
Feb 2018Apr 201893.2%+45.6%+181.3%
Feb 2025Nov 20254120.5%+45.0%+36.7%
Average30+10.9%

Frequently Asked Questions

Is MRK below its 200-week moving average?

No. Merck & Co. Inc. (MRK) is currently 17.3% above its 200-week moving average of $97.30. It would need to fall to $97.30 to cross below the line.

What is MRK's 200-week moving average price?

Merck & Co. Inc.'s 200-week moving average is $97.30 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.

What happens when MRK drops below its 200-week moving average?

MRK has crossed below its 200-week moving average 24 times in our data. On average, buying at that moment produced a one-year return of +10.9%. These dips have historically been decent entry points. These episodes lasted 30 weeks on average.

Is MRK a good value right now?

Here's what our data says about MRK as of 2026-03-20: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 70. Free cash flow yield is 4.2%. Return on equity is 36.9%. Price-to-book is 5.4x. This is not a buy or sell recommendation — always do your own research.

How does MRK compare to the S&P 500?

Over the past 33.2 years, $100 invested in MRK would have grown to $1796, compared to $2683 for the S&P 500. That's 9.1% annualized vs 10.4% for the index. MRK has underperformed the broader market over this period.

Does MRK pay a dividend?

Yes. Merck & Co. Inc. currently pays a dividend yield of 298.00%.

Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.

Data as of week of 2026-03-20